source
- Teva named stalking horse bidder to acquire BioXcel's neuroscience assets for $57.5 millionBioXcel Therapeutics, a Connecticut biotech focused on neuroscience, filed for Chapter 11 bankruptcy after running out of cash to fund operations through August. In the filing, the company selecte…
- CEPI pledges up to $16.5M to advance Egyptian biotech's Ebola vaccine candidateCEPI has committed up to $16.5 million to help bring Minapharm’s Bundibugyo Ebola vaccine candidate into clinical testing. The funding will support preclinical work and an early-stage human trial…